Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK

Ute Gick(University Hospital of Bern), Stefan Aebi(University of Lucerne), Walter Mingrone(Kantonsschule Olten), Christoph Rochlitz, Viviane Hess(University Hospital of Bern), Doris Lanz(Queen Mary University of London), Daniel Rauch(Washington University in St. Louis), Bernhard C. Pestalozzi(University of Zurich), Pierluigi Ballabeni(Swiss Group For Clinical Cancer Research)
Oncology
January 1, 2006
10.1159/000100449
Cited by 10

Related Papers

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
|Annals of Oncology|2017|396
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
|The Lancet|2000|286
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
|Annals of Oncology|2023|218
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184